Writing Group Disclosures.
| Writing Group Member |
Employment | Research Grant |
Other Research Support |
Speakers’ Bureau/ Honoraria |
Expert Witness | Ownership Interest |
Consultant/Advisory Board | Other |
|---|---|---|---|---|---|---|---|---|
| James F. Meschia | Mayo Clinic | NINDS† | None | None | None | None | None | None |
| Cheryl Bushnell | Wake Forest University Baptist Medical Center | World Federation of Neurology† | None | None | None | None | None | None |
| Bernadette Boden-Albala | New York University, Global Institute of Public Health | NIH† | None | None | None | None | None | None |
| Lynne T. Braun | Rush University Medical Center | NIH† | None | None | None | None | Nurse Practitioner Advisory Board*; UpToDate* | None |
| Dawn M. Bravata | Department of Veteran Affairs | Department of Veteran Affairs†; NIH/NHLBI† | None | None | None | None | None | None |
| Seemant Chaturvedi | University of Miami Miller School of Medicine | None | None | None | None | None | Abbott Vascular*; Boehringer-Ingelheim*; Thornhill Research* W.L. Gore* | None |
| Mark A. Creager | Brigham and Women’s Hospital | Medtronic†; NIH† | None | None | None | None | AstraZeneca†; Baxter Healthcare*; Merck (via TIMI Group)*; Novartis*; Takeda* | None |
| Robert H. Eckel | University of Colorado at Denver | None | None | None | None | None | Amarin*; Amylin*; Genetech*; Janssen, Johnson & Johnson*; Lilly*; Novo Nordisk*; Regulus*; Sanofi-Aventis* | None |
| Mitchell S.V. Elkind | Columbia University | BMS/Sanofi†; diaDexus, Inc† NIH† | None | None | Merck Organon (Nuvaring and stroke)†; Novartis (aliskiren and stroke)* | None | BMS-Pfizer Pharmaceutical Partnership*; Janssen*; Daiichi Sankyo*; Biogen IDEC* | None |
| Myriam Fornage | University of Texas Health Science Center at Houston | None | None | None | None | None | None | None |
| Larry B. Goldstein | Duke University | None | None | Pfizer* | None | None | Daiichi Sankyo* | None |
| Steven M. Greenberg | Massachusetts General Hospital | NIH/NINDS† | None | None | None | None | None | None |
| Susanna E. Horvath | Columbia University | None | None | None | None | None | None | None |
| Costantino Iadecola | Weill Cornell Medical College | None | None | None | None | None | None | None |
| Edward C. Jauch | Medical University of South Carolina | NIH/NINDS† | None | None | None | None | None | None |
| Wesley S. Moore | University of California at Los Angeles | None | None | None | None | None | None | None |
| John A. Wilson | Wake Forest School of Medicine | None | None | None | None | None | None | None |
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
*
Modest.
†
Significant.